SEC Form 4 · accession 0001193125-26-294708
Pyxis Oncology, Inc. · PYXS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jakob Dupont
Director
Period of report
Jun 30, 2026
Accepted (ET)
Jul 2, 2026 · 4:30 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001782223
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 30, 2026 | M | 35,000 | $1.60 | A | 73,741 | D | |
| Common StockF2,F3 | Jun 30, 2026 | S | 35,000 | $3.06 | D | 38,741 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F4 | $1.60 | Jun 30, 2026 | M | 35,000 | D | — | Sep 22, 2033 | Common Stock | 35,000 | 357,461 | D |
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on Septemeber 24, 2025.
- F2Reflects sales of common stock executed in multiple transactions. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected within the ranges set forth in footnotes 3 of this Form 4.
- F3The transaction was executed in multiple trades in prices ranging from $3.00 to $3.36.
- F4Award of stock options to purchase Common Shares with a vesting commencement date of August 23, 2024. These options vest and become exercisable in three equal annual tranches from August 23, 2023, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation).